Generic R & D benefits: 2017 US patent expiry drug TOP10

Source: Yaodu 2017-03-08 In 2017, many drugs will lose patent protection Based on market intelligence agencies, public securities filing documents, FDA information records, court documents and other resources, this paper screened 10 drugs that will lose patent in the United States this year These 10 drugs are the varieties of large pharmaceutical companies Over the years of listing, these drugs have brought considerable profits to the companies that own them 。 The total sales of the 10 drugs in the United States last year was more than $10 billion, covering multiple sclerosis, HIV, erectile dysfunction, cancer and other indications In 2017, many drugs will lose patent protection Based on market intelligence agencies, public securities filing documents, FDA information records, court documents and other resources, this paper screened 10 drugs that will lose patent in the United States this year These 10 drugs are the varieties of large pharmaceutical companies Over the years of listing, these drugs have brought considerable profits to the companies that own them 。 The total sales of the 10 drugs in the United States last year was more than $10 billion, covering multiple sclerosis, HIV, erectile dysfunction, cancer and other indications For brand drugs, patent expiration means the coming of generic competition, which indicates that the sales of brand drugs will decline, even precipitous decline, which is undoubtedly a blow to pharmaceutical enterprises, especially those heavy bomb drugs In order to make up for the sales loss caused by the expiration of brand drug patents, some pharmaceutical enterprises have also taken some countermeasures, including trying to extend the brand drug patent cycle, updating products, increasing new growth points, and even reducing costs through layoffs 1 Copaxone's common name: gratirepasone acetate was approved by FDA in 1996 Kepasson is one of TIWA's best-selling products According to its sales in the United States in 2016, it is also the heaviest variety facing generic competition this year, and its long-term preparations also face more worrying patent issues The loss date of the first generation of kepasone preparation was earlier than expected, and its new generation of long-acting preparation version faced the same problem Once the patent is lost, Tyva will lose billions of dollars On April 16, 2015, the US FDA approved the first generic kepasone The generic drug will be jointly developed by momenta and Suntech, a subsidiary of Novartis According to the FDA, the generic drug can completely replace kepasone in the treatment of patients with relapsing multiple sclerosis However, due to the patent problem of kepasone, the drug has not yet been put on the market Tyva tried to defend the franchise of kepasson through patent litigation, but it was not easy Last year, the company lost two key patents in patent litigation, and in January, the court ruled that four patents for its long-term version of the drug were invalid Analysts predict that Tyva's litigation efforts will not help 2 Cialis was approved by FDA in 2003 for erectile dysfunction and FDA in 2011 for benign prostatic hyperplasia Lilly's drug is not only listed in the top 10 list of drugs with expired U.S patents in 2017, but also faces the biggest sales decline Analysts at evaluate Pharma predict that sialis's sales in the United States will decline to $55 million in 2022, a 96% decline compared with $1.45 billion in 2016 Cialis is just one of three best-selling products that will lose patent protection in 2017 The company is relying on layoffs and cost cutting to get through a difficult period, and it is looking to new products, such as diabetes drugs, truccity and jardiance, to reverse the adverse situation 3 Viagra (Viagra) Viagra is a very familiar drug, which was initially developed as a heart disease drug, but it was found in clinical trials to have good effects on male erectile dysfunction The legendary blue pill will face generic competition by the end of this year Viagra has come a long way since it was approved in 1998 This drug is a reliable sales engine, which is partly due to Pfizer's product promotion ability in the international market In addition, the excellent formula of the drug also plays a role in promoting sales Pfizer has spent a lot of time on patent of Viagra preparation, and successfully extended the market monopoly of Viagra in the United States to 2019 But according to Pfizer's agreements with TIWA and mylan, the latter two companies will be able to sell their Viagra generics on December 11 this year Analysts predict Viagra's sales will fall to $359 million next year and $188 million in 2022 4 Velcade (Vanke) common name: bortezomii in 2015, Takeda pharmaceutical suffered a blow A patent of Velcade, a heavy drug with multiple myeloma, expired in 2022, was ruled invalid by a federal judge, which cleared the way for generic competition this year At present, Takeda is ready to accept the reality, and this day will soon come Analysts at evaluate Pharma predict Velcade will lose about $1 billion in sales by 2022 due to generic competition, down from $1.13 billion in 2016 to $187 million in 2022 At present, Teva's subsidiaries, atvis and Fresenius, have been approved for generic drugs of the drug Takeda is now looking to Velcade's follow-up oral drug, ninlaro, to make up for Velcade's losses from generic competition 5 In 2016, Bristol Myers Squibb made a lot of headlines for its cancer immunotherapy drugs But the company has also trumpeted its strong anti-virus franchise, including its anti HIV drug, Sustiva, which will lose its franchise in December, according to the company's 2016 securities filings Sustiva is a non nucleoside reverse transcriptase inhibitor that works by blocking the proliferation of HIV, with sales of $901 million in the United States in 2016 But a batch of generic drugs are waiting to land in the US market Companies such as TIWA, mercury, strides and Aurobindo have been temporarily approved for the generic Sustiva Sustiva's compound patent expires in 2013, while its method patent for HIV treatment expires next September But other patents are in dispute Bristol Myers Squibb previously won pediatric monopoly on the drug and extended its market monopoly for six months The monopoly expires in November, so generic drugs will be available in December Bristol Myers Squibb, which has been hit harder by patents, including its aripiprazole, is counting on new branded drugs to help cover those losses, including the company's immunooncology drug nafumab, which has annual sales of $3.8 billion 6 Sandostatin LAR (octreotide acetate microspheres for injection) although the Sandostatin LAR of Novartis lost patent protection in early 2017, the drug is expected to maintain a certain sales volume in the next few years Sandostatin's franchise also includes a quick release product Evaluate Pharma forecasts a small increase in Sandostatin franchise sales in 2017 and 2018, but a small drop to $820 million in the next few years At present, several companies are seeking to approve their generic drugs, but the product is difficult to copy, and its production and development are complex, so the market access threshold is high 7 Norditropin simplexx Norditropin simplexx is the only drug listed in the 2017 US patent expiration TOP10 of Novo Nordisk This product is a auxin preparation, and its patent expires at the end of this year Fortunately, because novo and Nordisk's pens are patented, the drug is unlikely to face generic competition in the short term In addition to the US, Norditropin will lose patent protection in Germany, China and Japan this year With this product, Novo Nordisk has become the global leader in auxin products, with Norditropin occupying 35% of the global market share The company introduced the product in the 1980s 8 Viread (tenofovir) Viread is the first drug in Gilead's new generation of nucleoside analogue reverse transcriptase inhibitors The drug was first approved for marketing in 2001, and Gilead then developed several compound drugs around the drug, including the heavyweight drug truvada Now, under a patent settlement with Gilead, Tyva will be able to launch its Viread generic by the end of this year The loss of Viread's patent rights is even worse for Gilead, because the company's sales of hepatitis C products are suffering from Waterloo Analysts predict that after the loss of patent protection, Viread's sales will fall sharply this year, to $15 million by 2022 9 Pristiq, Pfizer's antidepressant, went on the market in 2008, just as the patent of its predecessor, Effexor, expired Pristiq is an "improved" drug of venlafaxine, the active ingredient of Effexor Pristiq was originally developed by Wyeth, which was acquired by Pfizer in 2009 Pristiq's sales peaked at $737 million in 2014, fell to $715 million in 2015, and even fell to $578 million in 2016 According to FDA information, mylan, Lupin, atvis and Sandoz have been approved as pristiq generic drugs 10 Strattera (tormoxitine) in 2016, Strattera's sales in the United States were more than $500 million, but the sales of the drug began to decline By 2022, sales of the drug could be lower than any other drug on the list Strattera was first approved by FDA in 2002 So far, Apotex, Aurobindo, Sandoz, glenmark, sunpharma, mylan and Dr Reddy's have been temporarily approved as generic drugs of Strattera.